Adagene Inc. American Depositary Shares (ADAG)
Stock · NASDAQ · Health Care
$2.06as of 10/16/2026
Price chart
Active signals
ADAG Signal Track Record
How signals performed across all stocks →What ADAG's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 47 | -1.6% | 47% | September 15, 2026 |
| Bollinger Band BreakdownActive now | 24 | +2.2% | 54% | September 9, 2026 |
| Bollinger Band Breakout | 23 | -12.8% | 39% | August 5, 2026 |
| 200-Day Moving Average TouchActive now | 17 | -4.2% | 41% | September 9, 2026 |
| Any 20-session window (baseline) | -1.9% | 46% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ADAG
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 128
- Website
- www.adagene.com/
Fundamentals
- 1-day range
- $2.01$2.4
- Market cap
- $273.45M
- P/E (trailing)
- —
- P/E (forward)
- -3.68
- EPS (trailing)
- $-0.30
- Dividend yield
- —
- Beta
- 0.63
- Avg. volume
- 285.2K
Forecasts
6 analyst ratings
Adagene Inc. American Depositary Shares Competitors
Chosen by industry and closest market cap.
- ADAGAdagene Inc. American Depositary Shares$2.06▼ 14.17%Market cap $273.45MP/E —$1.3$4.85
- EBSEmergent BioSolutions Inc. Common Stock$6.38▼ 11.14%Market cap $273.98MP/E —$4.36$14.06
- CLLSCellectis S.A. American Depositary Shares$1.04▼ 5.88%Market cap $270.42MP/E —$1.04$4.75
- BCYCBicycle Therapeutics plc American Depositary Shares$3.46▼ 3.89%Market cap $277.87MP/E —$3.33$9.08
- PRQRProQR Therapeutics N.V. Ordinary Shares$1.31▼ 9.66%Market cap $268.13MP/E —$1.33$3.1
- ELDNEledon Pharmaceuticals Inc. Common Stock$2.13▼ 6.17%Market cap $267.07MP/E —$1.35$4.6
- TRDAEntrada Therapeutics Inc. Common Stock$4.37▼ 8.58%Market cap $266.70MP/E —$4.11$16.45
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ADAG Adagene Inc. American Depositary Shares | $273.45M | — | $2.06 | ▼ 14.17% | $1.3$4.85 |
| EBS Emergent BioSolutions Inc. Common Stock | $273.98M | — | $6.38 | ▼ 11.14% | $4.36$14.06 |
| CLLS Cellectis S.A. American Depositary Shares | $270.42M | — | $1.04 | ▼ 5.88% | $1.04$4.75 |
| BCYC Bicycle Therapeutics plc American Depositary Shares | $277.87M | — | $3.46 | ▼ 3.89% | $3.33$9.08 |
| PRQR ProQR Therapeutics N.V. Ordinary Shares | $268.13M | — | $1.31 | ▼ 9.66% | $1.33$3.1 |
| ELDN Eledon Pharmaceuticals Inc. Common Stock | $267.07M | — | $2.13 | ▼ 6.17% | $1.35$4.6 |
| TRDA Entrada Therapeutics Inc. Common Stock | $266.70M | — | $4.37 | ▼ 8.58% | $4.11$16.45 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell EngagerYahoo · 9/22/2026
- China’s NMPA Approves Adagene’s IND Application For ADG138, Double-Masked HER2×CD3 Bispecific T Cell Engager Built On Proprietary SAFEbody Precision Masking TechnologyBenzinga · 9/22/2026
- Adagene Inc. (ADAG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/15/2026
- HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $7 Price TargetBenzinga · 9/14/2026
Insider Activity
Insider Actions →- Tam Man Kin · September 23, 2026 · Buy2.0K @ $3
- Peter Luo · September 16, 2026 · Buy20.3K @ $3.15
- Cuong Do V · August 14, 2026 · Buy2.0K @ $3.75
- Zhu Li · August 13, 2026 · Grant20.0K
- Cheung Andy Yiu Leung · August 13, 2026 · Grant20.0K
- Cuong Do V · August 13, 2026 · Grant20.0K
- Grawunder Ulf · August 13, 2026 · Grant20.0K
- Peter Luo · August 5, 2026 · Buy279 @ $3.65
- Peter Luo · August 4, 2026 · Buy23.0K @ $3.65
Institutional Ownership
March 31, 2026
- Total shares held
- 3.30M
- Total value held
- $9.70M
- Institutional holders
- 24
- Unknown1.34M
- Unknown736.8K
- Unknown607.9K
- Unknown199.6K
- Unknown66.1K
- Unknown47.1K
- Unknown40.3K
- Unknown38.1K
- Unknown35.1K
- Unknown34.8K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Adagene's ADG138 IND approved by China's NMPA
China's National Medical Products Administration has cleared Adagene's Investigational New Drug application for ADG138, a HER2xCD3 bispecific T-cell engager. This regulatory step allows the company to proceed with clinical development of its proprietary SAFEbody technology in China. The stock is currently trading near its 52-week low, well below the average analyst target price.
Adagene's ADG138 IND approved by China's NMPA. China's National Medical Products Administration has cleared Adagene's Investigational New Drug application for ADG138, a HER2xCD3 bispecific T-cell engager. This regulatory step allows the company to proceed with clinical development of its proprietary SAFEbody technology in China. The stock is currently trading near its 52-week low, well below the average analyst target price.